Table 1.

Immunization regimen

GroupImmunizationMacaque
PrimaryBooster(s)a
Argp160rgp16091286
91292
91268
91262
Bv-SE5 (gp160)rgp160J90304
91272
91250
91263
Cv-SE6 (gp130)rgp13091255
91254
91244
91293
Dv-SG11 (Gag-Pol)Gag-Pol particles91245
91278
91288
91253
Ev-SE5 + v-SG11b Gag-Pol particles + rgp160c 91251
91281
91248
91283
Fv-SGE14 (Gag-Pol-gp160)d Gag-Pol-Env particlese 91287
91291
91282
91247
Control91077
91078
M92387
93057
  • a Booster immunizations were performed by intramuscular injections at 3, 18, and 24 months after the primary immunization.

  • b Animals received equal doses (108PFU) of each recombinant virus administered separately by skin scarification at opposite sites along the midline of the back.

  • c Inoculum was formulated as a mixture of core particles (containing 500-μg equivalents of p27 antigen) and rgp160 (100 μg).

  • d Inoculum contained a single recombinant virus (108 PFU) expressing the gag-pol genes under the control of vaccinia 40K promoter and the full-length envgene under the 7.5K promoter.

  • e Immunogen was produced from recombinant vaccinia virus-infected cells and was composed of both the core (Gag-Pol) and the envelope antigens in a mature virus-like particle structure (pseudovirions). Each inoculum contained a 500-μg equivalent of p27 antigens and approximately 30 μg of envelope proteins.